determine reasons for hospital readmissions. 12 In the schema for our study, these reasons included symptoms, fever without a source, febrile neutropenia, confirmed infection, dehydration/electrolyte abnormalities, planned hospitalization
Search Results
P. Connor Johnson, Caron Jacobson, Alisha Yi, Anna Saucier, Tejaswini M. Dhawale, Ashley Nelson, Mitchell W. Lavoie, Mathew J. Reynolds, Carlisle E.W. Topping, Matthew J. Frigault, and Areej El-Jawahri
Keli Turner, Sheelu Varghese, and H. Richard Alexander
symptoms are abdominal pain and increasing abdominal girth, the latter of which may be caused by ascites. 12 , 13 Weight loss and fever are other less-common presenting symptoms. 12 , 13 In some series, a palpable abdominal mass has been described on
Meena A. Prasad and Laura M. Kulik
.4% vs 61.5%; P =.0493). 30 Table 2 Factors to Consider Before RFA Unfortunately, more than 50% of patients undergoing TACE develop symptoms of postembolization syndrome, consisting of abdominal pain, fever, nausea, and vomiting. In
Saurabh Rajguru and Brad S. Kahl
). Toxicity was not insignificant, with 17% and 12% of patients hospitalized for grade 3 and 4 adverse events (AEs), respectively—mostly neutropenic fever. The 4-year PFS and OS rates were 73% and 81%, respectively. 10 An update after 6 years of follow
David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen, and Diana I. Brixner
myalgias, fatigue, fever, edema, and headache. Among patients experiencing an ADE, 10 (32%) had a dose reduction. The median time to dose reduction was 52 days, and the new median dose was 300 mg/d. A total of 6 patients (19%) discontinued imatinib because
Jeffrey S. Montgomery, David C. Miller, and Alon Z. Weizer
to 71% of patients experiencing urinary frequency, 67% cystitis, 25% fever, and 23% hematuria. Serious local and systemic infections from BCG occur and may require antituberculosis therapy and even hospitalization. Although the use of BCG should be
Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Robin M. Lally, Terry S. Langbaum, Allison L. McDonough, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass
avoidance of zoonosis, travel precautions, and gardening precautions. 121 – 126 Contact with pets did not increase the risk of fever, bacteremia, pneumonia, and gastroenteritis in children with acute myeloid leukemia, 127 and the panel believes that
Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J. Fry, Morgan Garber, Rebecca A. Gardner, Lauren Gurschick, Patricia Kropf, Jeff J. Reitan, Craig Sauter, Bijal Shah, Elizabeth J. Shpall, and Steven T. Rosen
duration of 1 week. The first sign of CRS is usually fever, which can progress to hypotension and/or hypoxia; other signs and symptoms may include arrhythmias, coagulopathies, tachycardia, and other organ toxicities. 62 , 63 Management strategies have been
Damon Reed, Ragini Kudchadkar, Jonathan S. Zager, Vernon K. Sondak, and Jane L. Messina
pediatric population are used to justify interferon use in the pediatric melanoma population. In adults, the side-effect profile deters many patients from receiving interferon: toxicity such as fevers, fatigue, myalgias/arthralgias, and depression limit
Leslie A. Fecher, Shrinivas Bishu, Robert J. Fontana, Salim S. Hayek, and Bryan J. Schneider
Patients are rarely symptomatic; however, some may present with fever. Other more common causes of renal dysfunction, such as dehydration or exposure to nephrotoxins like nonsteroidal anti-inflammatory drugs, contrast agents, bisphosphonates, and proton
